Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31319278 | 0.90 | ADORA2A (0.46) | CA1CA2ADORA2AXDHCYP11B2 | |
| SCHEMBL31319129 | 0.86 | CYP11B1 (0.38) | ADORA2ACYP11B2CYP11B1GSK3B | |
| SCHEMBL29057760 | 0.81 | XDH (0.46) | CA1CA2XDHSTS | |
| SCHEMBL26635433 | 0.81 | XDH (0.35) | CA1CA2XDHCYP11B2CYP11B1 | |
| SCHEMBL5598955 | 0.78 | PTGDR2 (0.46) | CA1CA2CYP11B2CYP11B1CSNK1A1 | |
| SCHEMBL31319200 | 0.76 | USP8 (0.35) | ADORA2AXDHCYP11B2USP8USP7 | |
| SCHEMBL26635333 | 0.76 | MAP4K4 (0.36) | CA1CA2CYP11B2CYP11B1STS | |
| SCHEMBL26635345 | 0.75 | XDH (0.52) | XDHUSP8USP7 | |
| SCHEMBL29683759 | 0.75 | MMP3 (0.52) | CA2STSUSP7 | |
| SCHEMBL24820105 | 0.75 | EIF4E (0.50) | XDHPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2024243502-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | CA1 4855/4885CA2 4566/4885ADORA2A 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.